BD750 是一个有效的免疫抑制剂，是JAK3/STAT5的抑制剂，可抑制 IL-2 诱导的、JAK3/STAT5 依赖的 T 细胞增殖，其抑制小鼠和人 T 细胞增殖的IC50值分别为 1.5 μM 和 1.1 μM。
| 生物活性 | BD750, an effective immunosuppressant and aJAK3/STAT5inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC50values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively[1][2]. |
| IC50& Target[2] | |
体外研究
(In Vitro) | BD750 inhibits human T cell proliferation stimulated either by anti-CD3/anti-CD28 mAbs or by alloantigen in a dose-dependent manner with IC50values of 1.1 ± 0.2 μM and 1.3 ± 0.2 μM respectively[1].
BD750 also inhibits ConA, PMA/ionomycine or alloantigen-induced mouse T cell proliferation and PHA or PMA/ionomycine-induced human T cell proliferation[1].
BD750 (5 or 20 μM) inhibits the LPS-induced JAK-STAT5 signaling in DC[2].
Western Blot Analysis[2] | Cell Line: | Purified immature DCs. | | Concentration: | 1, 5 or 20 μM. | | Incubation Time: | 12 h. | | Result: | Had fewer small dendrites and smaller clusters than typical mDCs (5 or 20 μM).
At a higher dose significantly reduced the levels of LPS-stimulated IL-6, IL-12, TNF-α, IL-1β and IL-23 production by DCs.
|
|
体内研究
(In Vivo) | BD750 can induce tolerogenic dendritic cells (tolDC) and their function in experimental autoimmune encephalitis (EAE) in mice[2].
| Animal Model: | Female C57BL/6 mice (10 wks old, 19-21 g)[2]. | | Dosage: | 20 μM. | | Administration: | IV, treated DC on d 7, 11 and 15 post the first PTX injection (dpi 7, 11 and 15). | | Result: | Significantly reduced the frequency of Th1 and Th17 cells and increased the percentage of Tregs compared with mice receiving PBS. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 125 mg/mL(460.68 mM;Need ultrasonic) 配制储备液 | 1 mM | 3.6854 mL | 18.4271 mL | 36.8541 mL | | 5 mM | 0.7371 mL | 3.6854 mL | 7.3708 mL | | 10 mM | 0.3685 mL | 1.8427 mL | 3.6854 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (7.67 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (7.67 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
*以上所有助溶剂都可在本网站选购。 |
m.cnreagent.com